Core Viewpoint - The company reported a steady growth in revenue and profit for the first half of 2025, indicating strong performance in both domestic and international markets [1] Financial Performance - The company's operating revenue reached 6.016 billion RMB, representing a year-on-year increase of 12.79% [1] - Net profit attributable to shareholders was 999.8 million RMB, up 5.03% year-on-year [1] - The net profit excluding non-recurring gains and losses was 966 million RMB, reflecting a year-on-year growth of 21.01% [1] - Basic earnings per share were 1.21 RMB [1] - The company plans to distribute a cash dividend of 1.3 RMB per 10 shares (including tax) to all shareholders [1] Business Growth - The company achieved stable growth in domestic revenue due to the accelerated implementation of industry policies and its competitive product advantages [1] - Internationally, the company experienced significant growth, with overseas revenue increasing by 22.48% to 1.142 billion RMB, accounting for 18.99% of total revenue [1] - The overseas business has become a crucial driver for the company's sustained growth [1]
联影医疗(688271.SH)发布上半年业绩,归母净利润9.98亿元,增长5.03%